![Arkadiusz Dudek](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Arkadiusz Dudek is the founder of TTC Oncology LLC, established in 2015, serving as Chief Medical Officer.
Current jobs include Independent Director at SquareX Pharmaceuticals Corp.
since 2018 and Chief Medical Officer at Luminary Therapeutics, Inc. since 2019.
Former jobs include Director at Martell Diagnostic Laboratories, Inc. from 2014 to 2021 and Chief Medical Officer at Vanquish Oncology, Inc. from 2013 to 2020.
Education includes a doctorate from the University of Warsaw.
| Sociétés | Poste | Début |
|---|---|---|
SquareX Pharmaceuticals Corp.
 SquareX Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage pharmaceutical company that develops pharmaceuticals for cold sores | Directeur/Membre du Conseil | 01/01/2018 |
Ttc Oncology LLC
 Ttc Oncology LLC Medical/Nursing ServicesHealth Services TTC Oncology LLC is a biopharmaceutical company focused on developing safer and more effective treatments for metastatic estrogen receptor-positive (ER+) breast cancer. The company is based in Minneapolis, MN. The company holds a worldwide license from the University of Illinois Chicago for a novel therapeutic approach targeting the estrogen receptor in ER+ breast cancer. Its lead product, TTC-352, is a selective human estrogen receptor partial agonist (SHERPA) designed for patients who have failed first-line endocrine therapies and CDK4/6 inhibitors, and is delivered orally. TTC Oncology is also developing a biomarker (PKC? overexpression) to predict treatment benefit. The company was founded in 2015 by Arkadiusz Dudek, Debra A. Tonetti, Gregory Thatcher. Debra A. Tonetti has been the CEO of the company since 2015. | Fondateur | 01/07/2015 |
Luminary Therapeutics, Inc.
 Luminary Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Develops non-viral autologous cell therapies | Directeur Technique/Scientifique/R&D | 01/01/2019 |
| Sociétés | Poste | Fin |
|---|---|---|
Martell Diagnostic Laboratories, Inc.
 Martell Diagnostic Laboratories, Inc. Medical SpecialtiesHealth Technology Develops and promotes tumor biomarker tests | Directeur/Membre du Conseil | 01/01/2021 |
Vanquish Oncology, Inc.
 Vanquish Oncology, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs focused on targeting molecular defects in specific cancer cells to create personalized oncology therapeutics for unmet and underserved cancer markets | Directeur Technique/Scientifique/R&D | 01/01/2020 |
Actives
Inactives
Sociétés cotées
Entreprise privées
| Entreprise privées | 6 |
|---|---|
Martell Diagnostic Laboratories, Inc.
Martell Diagnostic Laboratories, Inc. Medical SpecialtiesHealth Technology Develops and promotes tumor biomarker tests | Health Technology |
Vanquish Oncology, Inc.
Vanquish Oncology, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs focused on targeting molecular defects in specific cancer cells to create personalized oncology therapeutics for unmet and underserved cancer markets | Health Technology |
University of Warsaw
 University of Warsaw Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Luminary Therapeutics, Inc.
Luminary Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Develops non-viral autologous cell therapies | Commercial Services |
SquareX Pharmaceuticals Corp.
SquareX Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage pharmaceutical company that develops pharmaceuticals for cold sores | Health Technology |
Ttc Oncology LLC
Ttc Oncology LLC Medical/Nursing ServicesHealth Services TTC Oncology LLC is a biopharmaceutical company focused on developing safer and more effective treatments for metastatic estrogen receptor-positive (ER+) breast cancer. The company is based in Minneapolis, MN. The company holds a worldwide license from the University of Illinois Chicago for a novel therapeutic approach targeting the estrogen receptor in ER+ breast cancer. Its lead product, TTC-352, is a selective human estrogen receptor partial agonist (SHERPA) designed for patients who have failed first-line endocrine therapies and CDK4/6 inhibitors, and is delivered orally. TTC Oncology is also developing a biomarker (PKC? overexpression) to predict treatment benefit. The company was founded in 2015 by Arkadiusz Dudek, Debra A. Tonetti, Gregory Thatcher. Debra A. Tonetti has been the CEO of the company since 2015. | Health Services |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
